{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:29:40Z","timestamp":1793449780442,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1136\/ard-2022-222543","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T18:25:11Z","timestamp":1670264711000},"page":"331-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":165,"title":["Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01262118","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484561","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00147498","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413660","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00550446","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00603512","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00687193","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01164579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00976599","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01059864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01359150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02147587","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01039688","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02281552","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02831855","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00661661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jeffrey R","family":"Curtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent M","family":"Gunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonobu","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Vranic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J","family":"G\u00f3mez-Reino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222543_bib1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222543_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222543_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/hon.2525","article-title":"Rheumatoid arthritis and lymphoma: incidence, pathogenesis, biology, and outcome","volume":"36","author":"Klein","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1136\/ard-2022-222543_bib4","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222543_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-222543_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222543_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13075-017-1482-y","article-title":"The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs","volume":"19","author":"Cho","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222543_bib8","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.1780400906","article-title":"Rheumatoid arthritis and the risk of malignancy","volume":"40","author":"Cibere","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222543_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaccao.2020.12.003","article-title":"Cardiovascular risk factors are associated with future cancer","volume":"3","author":"Lau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1136\/ard-2022-222543_bib10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"10.1136\/ard-2022-222543_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","article-title":"Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Leiva","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1136\/ard-2022-222543_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222543_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0010-4825(92)90023-G","article-title":"Simple SAS macros for the calculation of exact binomial and Poisson confidence limits","volume":"22","author":"Daly","year":"1992","journal-title":"Comput Biol Med"},{"key":"10.1136\/ard-2022-222543_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and Life-Tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1136\/ard-2022-222543_bib15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-222543_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/aos\/1176345693","article-title":"Piecewise exponential models for survival data with covariates","volume":"10","author":"Friedman","year":"1982","journal-title":"Ann Statist"},{"key":"10.1136\/ard-2022-222543_bib17","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","author":"Charles-Schoeman","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222543_bib18","author":"American College of Cardiology"},{"key":"10.1136\/ard-2022-222543_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222543_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222543_bib21","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation","volume":"68","author":"van Halm","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222543_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"key":"10.1136\/ard-2022-222543_bib23","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/heartjnl-2019-316193","article-title":"Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study","volume":"106","author":"Nikiphorou","year":"2020","journal-title":"Heart"},{"key":"10.1136\/ard-2022-222543_bib24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.20855","article-title":"The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years","volume":"52","author":"Nicola","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222543_bib25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222543_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","article-title":"Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222543_bib27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ijc.31407","article-title":"Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions","volume":"143","author":"Calip","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1136\/ard-2022-222543_bib28","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222543_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bjc.2011.252","article-title":"Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies","volume":"105","author":"Vinogradova","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1136\/ard-2022-222543_bib30","first-page":"3418975","article-title":"Role of nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion","volume":"2019","author":"Wong","year":"2019","journal-title":"Adv Pharmacol Sci"},{"key":"10.1136\/ard-2022-222543_bib31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/DSS.0000000000000694","article-title":"Prevalence and clinical characteristics of nonmelanoma skin cancers among Hispanic and Asian patients compared with white patients in the United States: a 5-year, single-institution retrospective review","volume":"42","author":"Loh","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1136\/ard-2022-222543_bib32","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1046\/j.1365-2133.2000.03892.x","article-title":"Changing trends in non-melanoma skin cancer in South Wales, 1988-98","volume":"143","author":"Holme","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard-2022-222543_bib33","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-222543_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-222543_bib35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1136\/ard-2022-222543_bib36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2174\/138161212799504786","article-title":"The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis","volume":"18","author":"Peters","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1136\/ard-2022-222543_bib37","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-222543_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/ar2751","article-title":"Rheumatoid arthritis and smoking: putting the pieces together","volume":"11","author":"Baka","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222543_bib39","doi-asserted-by":"crossref","first-page":"22279","DOI":"10.3390\/ijms151222279","article-title":"Smoking and rheumatoid arthritis","volume":"15","author":"Chang","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1136\/ard-2022-222543_bib40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.rdc.2010.03.001","article-title":"Immune aging and rheumatoid arthritis","volume":"36","author":"Goronzy","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2022-222543_bib41","first-page":"19","article-title":"Cardiovascular risks associated with gender and aging","volume":"6","author":"Rodgers","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1136\/ard-2022-222543_bib42","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","article-title":"Age and cancer risk: a potentially modifiable relationship","volume":"46","author":"White","year":"2014","journal-title":"Am J Prev Med"},{"key":"10.1136\/ard-2022-222543_bib43","first-page":"1940","article-title":"Malignancies in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular risk factor: results from a Phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222543_bib44","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for Company-Sponsored Biomedical Research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724085054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724085054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:36:14Z","timestamp":1739522174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724085054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0003496724085054"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222543","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}